Status:
COMPLETED
Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD
Lead Sponsor:
NYU Langone Health
Conditions:
Alzheimer Disease
Eligibility:
All Genders
20-85 years
Brief Summary
Aging is the primary risk factor in aging-related dementia. An important initiating factor for the development and progression of cognitive impairment is disruption of the blood-brain barrier (BBB). B...
Eligibility Criteria
Inclusion
- Subjects that have been diagnosed with aMCI ages 65-85
Exclusion
- Pregnant, planning to get pregnant, or nursing.
- Claustrophobia
- Cardiac pacemaker
- Intracranial clips, metal implants, unremovable jewelries, metal in eyes.
- History or presence of any other major medical, neurologic or psychiatric conditions, such as Alzheimer's diseases, Parkinson's diseases, and stroke.
- Renal or liver disease as this may cause concerns related to Gad-based contrast agent
- Allergy to the contrast agent Gadolinium
Key Trial Info
Start Date :
December 18 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 11 2023
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT03389698
Start Date
December 18 2018
End Date
July 11 2023
Last Update
January 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016